Close
  Indian J Med Microbiol
 

Figure 3: (A, B) Pegylated interferon (PEG IFN) alfa-2a in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. In this randomized, controlled trial, the rates of response 24 weeks after therapy (normal ALT level and serum HBV DNA < 20,000 copies / mL) were higher in the two groups that received PEG IFN alfa-2a (with or without lamivudine) than in the group that received lamivudine. There was no difference in response rates between the group that received PEG IFN alfa-2a alone and the group that received the PEG IFN alfa-2a plus lamivudine. (Marcellin P et al., NEJM, 2004)

Figure 3: (A, B) Pegylated interferon (PEG IFN) alfa-2a in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. In this randomized, controlled trial, the rates of response 24 weeks after therapy (normal ALT level and serum HBV DNA < 20,000 copies / mL) were higher in the two groups that received PEG IFN alfa-2a (with or without lamivudine) than in the group that received lamivudine. There was no difference in response rates between the group that received PEG IFN alfa-2a alone and the group that received the PEG IFN alfa-2a plus lamivudine. (Marcellin P <i>et al</i>., NEJM, 2004)